Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean

Vaccine
Alba Maria Ropero-ÁlvarezM Velandia-González

Abstract

As part of the vaccination activities against influenza A[H1N1]pdm vaccine in 2009-2010, countries in Latin American and the Caribbean (LAC) implemented surveillance of events supposedly attributable to vaccines and immunization (ESAVI). We describe the serious ESAVI reported in LAC in order to further document the safety profile of this vaccine and highlight lessons learned. We reviewed data from serious H1N1 ESAVI cases from LAC countries reported to the Pan American Health Organization/World Health Organization. We estimated serious ESAVI rates by age and target group, as well as by clinical diagnosis, and completed descriptive analyses of final outcomes and classifications given in country. A total of 1000 serious ESAVI were reported by 18 of the 29 LAC countries that vaccinated against A[H1N1]pdm. The overall reporting rate in LAC was 6.91 serious ESAVI per million doses, with country reporting rates ranging from 0.77 to 64.68 per million doses. Rates were higher among pregnant women (16.25 per million doses) when compared to health care workers (13.54 per million doses) and individuals with chronic disease (4.03 per million doses). The top three most frequent diagnoses were febrile seizures (12.0%), Guillain-Barré Syndrom...Continue Reading

References

Apr 9, 2008·Expert Review of Vaccines·Lucia Helena de OliveiraJon Kim Andrus
Sep 26, 2009·BMC Public Health·Alba Maria Ropero-ÁlvarezJon Kim Andrus
Apr 20, 2011·Vaccine·Xavier KurzAna Hidalgo-Simon
Nov 1, 2011·Archives of Medical Research·Patricia VidalVesta L Richardson
Dec 14, 2011·Vaccine·Alba Maria Ropero-ÁlvarezCuauhtémoc Ruiz-Matus

Citations

Sep 30, 2016·The World Allergy Organization Journal·Stephen C DreskinLanny J Rosenwasser
Jul 7, 2017·Obstetric Medicine·Viroj Wiwanitkit

Related Concepts

Seizure, Febrile, Simple
Variolation
Influenza
Trivalent Live Attenuated Influenza Vaccine
Experimental Lung Inflammation
Guillain-Barre Syndrome
Influenza A Virus, H1N1 Subtype
Pandemics
Chronic Disease
Classification

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.